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Purpose: Adjuvant chemotherapy (aCT) in rectal cancer patients who have undergone curative resection after neoadju-
vant chemoradiation (nCRT) is controversial. We aimed to investigate the benefits of using aCT and the clinical impact of 
completing aCT in ypstage 2 rectal cancer patients.
Methods: We retrospectively reviewed clinicopathological data from patients who had undergone radical resection after 
nCRT between January 2006 and December 2012. In total, 152 patients with ypT3/4N0M0 rectal cancer were included. 
Of these patients, 139 initiated aCT, while 13 did not receive aCT (no-aCT). Among those who received aCT, 132 patients 
completed their planned cycles (aCT-completion) whereas 7 did not (aCT-incompletion). All patients received long-
course chemoradiation; a 5-fluorouracil-based regimen was used for nCRT in most patients. The prognostic factors af-
fecting disease-free survival (DFS) and overall survival (OS) were analyzed.
Results: The median follow-up duration was 41 months. Demographic data did not differ significantly among the 3 
groups. In multivariate analysis, open surgery, a tumor size >2 cm, retrieval of <12 lymph nodes, circumferential resection 
margin (CRM) positivity and aCT incompletion were independent prognostic factors for poor DFS. Old age (≥60 years), 
open surgery, CRM positivity, aCT incompletion, and lack of aCT initiation compared to aCT completion were indepen-
dent prognostic factors for poor OS.
Conclusion: In ypstage 2 rectal cancer patients, aCT after nCRT and total mesorectal excision affected both DFS and OS; 
however, only patients who completed planned aCT exhibited survival benefits. Therefore, improving patients’ compli-
ance with the completion of aCT is desirable.
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INTRODUCTION
Neoadjuvant chemoradiation (nCRT) followed by total mesorec-
tal excision (TME) has been established as a standard therapeutic 
strategy for locally advanced rectal cancer, based on evidence 
from randomized controlled trials (RCTs) [1-6]. However, adju-
vant chemotherapy (aCT) following TME after nCRT is an ex-
trapolation of this therapeutic strategy for colon cancer [7, 8]. The 
national as well as National Comprehensive Cancer Network 
guidelines recommend aCT after nCRT and TME, irrespective of 
the final pathological report [9].
Recent studies have had contradictory results on the benefits of 
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aCT after nCRT and TME, but there has been increasing evidence 
that good responders displaying node negativity after nCRT do 
not benefit from aCT [10-17]. Therefore, some investigators have 
suggested that aCT should not be routinely applied after nCRT in 
good responders [10-12]. However, even if node negativity is con-
firmed after nCRT and TME, when standard treatment strategies 
for high-risk stage 2 colon cancer patients are considered, con-
cerns may arise that omitting aCT will lead to unfavorable onco-
logic outcomes in patients with advanced T stages (ypT3/4).
Importantly, studies suggesting a lack of benefit from aCT after 
nCRT in good responders only included patients who had com-
pleted their scheduled aCT, or did not clarify whether the patients 
had completed their scheduled aCT [10-13]. Therefore, these pa-
tients were not representative of real-world patients, considering 
the poor compliance with aCT after nCRT and TME in rectal 
cancer patients; thus, these studies may have underestimated the 
effects of aCT. Since previous studies have demonstrated that aCT 
incompletion worsens the prognosis of colon cancer patients, 
there may be important clinical implications to investigating the 
oncologic impact of aCT incompletion after nCRT and TME, 
along with aCT initiation.
Therefore, this study investigated the benefits of aCT initiation 
and the oncologic impact of aCT completion after nCRT and 
TME in ypstage 2 (ypT3/4N0M0) rectal cancer patients.
METHODS
From a prospectively collected database, we identified patients 
who had undergone curative resection after nCRT from January 
2006 to December 2012 and who exhibited ypN0 on their final 
pathological reports. Patients who had histories of malignancies 
in other organs within 5 years, had been diagnosed with heredi-
tary colorectal cancer or recurrent rectal cancer, had undergone 
palliative surgery or had been treated postoperatively with addi-
tional radiotherapy (RT) were excluded. Patients who underwent 
surgery or switched treatment regimens for palliative purposes 
due to early local recurrence (LR) or distant metastasis (DM) dur-
ing the 4 months of planned aCT were also excluded from the fi-
nal analysis. This study was approved by the Institutional Review 
Board of Severance Hospital (4-2018-1130) for exemption of in-
formed consent.
In total, 152 patients were included, of whom 139 received aCT 
and 13 did not. We retrospectively reviewed the patients’ elec-
tronic medical data to obtain each patient’s age, sex, body mass 
index, American Society of Anesthesiologists physical status clas-
sification, preoperative carcinoembryonic antigen (CEA) level, 
tumor level, clinical stage, nCRT regimen, name and type (mini-
mally invasive [laparoscopic or robotic] vs. open) of surgery, anas-
tomotic leakage, hospital stay, histology, tumor regression grade 
(Mandard grade), pathological stage, tumor size, number of re-
trieved nodes, circumferential resection margin (CRM), lympho-
vascular invasion, radicality of resection, initiation and comple-
tion of aCT, and aCT regimen. Variables were compared among 
patients who did not receive aCT (no-aCT), patients who initiated 
but did not complete aCT (aCT-incompletion) and patients who 
completed aCT (aCT-completion). We analyzed factors affecting 
disease-free survival (DFS) and overall survival (OS). Completion 
of aCT was defined as the completion of scheduled aCT, and in-
completion was defined as discontinuation within 4 months of 
aCT initiation for any reason.
For pretreatment workups, a digital rectal exam, colonoscopy, 
abdominopelvic computed tomography (CT), pelvic magnetic 
resonance imaging (MRI) and chest CT were conducted, and the 
clinical stage was determined based on the results of these pre-
treatment workups. Patients with clinical T3/4Nany or TanyN+ 
cancers were treated with nCRT. For the nCRT protocol, the ma-
jority of patients received 5-fluorouracil (5-FU)-based long-
course RT (5-FU 400 mg/m2/day and leucovorin [LV] 20 mg/m2/
day for 5 days on days 1–5 and days 29–33 or capecitabine 825 
mg/m2 twice daily for 5 days/wk during long-course RT [45–50.4 
Gy in 25–28 fractions]). An irinotecan plus S-1 regimen was also 
used in some patients.
TME was performed within 4–8 weeks of the completion of 
nCRT. Within 4–6 weeks of surgery, aCT was administered. The 
regimens for aCT included a bolus injection of FL (5-FU 400 mg/
m2/day and LV 20 mg/m2/day for 5 days every 4 weeks for 4 cy-
cles) or oral capecitabine (1,250 mg/m2 twice daily for 2 weeks ev-
ery 3 weeks for 6 cycles) and a FOLFOX regimen (infusion of ox-
aliplatin 85 mg/m2 and LV 200 mg/m2 followed by a bolus of 
5-FU 400 mg/m2 and continuous infusion of 5-FU 2400 mg/m2 
for 2 days every 2 weeks for 8 cycles). We defined incompletion of 
aCT as administration of aCT for less than 4 months.
The patients were followed up every 3 months for 2 years, and 
then every 6 months for the next 3 years. Physical examinations 
and chest X-rays were performed and CEA levels were assessed at 
every visit. Abdominopelvic CT and chest CT were performed at 
every 6-month and 1-year follow-up, respectively. Colonoscopies 
were performed 1, 3, and 5 years after surgery. Liver MRI, pelvic 
MRI or 18-fluorodeoxyglucose-positron emission tomography 
was performed as needed. DFS was defined as the time to disease 
progression; OS was defined as the time interval between surgery 
and death.
Categorical variables were analyzed by the chi-square test or 
Fisher exact test, and continuous variables were analyzed by Stu-
dent t-test or the Mann-Whitney U-test. Kaplan-Meier curves were 
constructed for OS and DFS, and survival outcomes were com-
pared through a log rank test. Prognostic factors for DFS and OS 
were analyzed with a Cox regression model. P-values <0.05 were 
considered statistically significant. IBM SPSS Statistics ver. 23.0 
(IBM Co., Armonk, NY, USA) was used for statistical analyses.
RESULTS
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follow-up duration was 41 months (interquartile range [IQR], 
30–56 months). The mean age of the patients was 58.8 ± 11.53 
years, and 106 patients were male (69.7%). In total, 116 patients 
received 5-FU-based nCRT (76.3%).
In 13 patients, aCT was not initiated after nCRT and TME: 6 
patients refused aCT, 4 developed postoperative complications 
such as a rectovaginal fistula, anastomotic leakage or surgical site 
infection, 1 developed a brain infarction after surgery, 1 devel-
oped hepatic encephalopathy after surgery, and 1 developed se-
vere hand-foot syndrome after nCRT. In the remaining 139 pa-
tients, aCT was initiated after nCRT and TME. Among them, 132 
patients completed their planned aCT schedules, whereas 7 did 
not. Of these 7, 2 stopped receiving aCT due to severe side effects 
of the chemotherapeutic agents, 1 refused to complete the 
planned schedule and 4 discontinued their aCT for reasons that 
were not recorded.
The patients’ demographics are shown in Table 1. There were no 
significant differences in patient characteristics among the 3 
groups. The 5-year DFS and OS rates of patients with ypstage 2 
cancer were 72.5% and 85.3%, respectively. The 5-year DFS rate 
was 74.8% in the aCT-completion group, 42.9% in the aCT-in-
completion group and 58.9% in the no-aCT group; the DFS 
curves differed significantly with a P-value of 0.029 (Fig. 1A). Re-
garding the sites of recurrence, the 5-year LR-free survival rates 
were 91.6%, 57.1%, and 64.3% (P = 0.001), and the 5-year DM-
free survival rates were 81.1%, 57.1%, and 59.3% (P = 0.155) in 
the aCT-completion, aCT-incompletion and no-aCT groups, re-
spectively. The 5-year OS rate was 88.7% in the aCT-completion 
group, 53.6% in the aCT-incompletion group and 76.9% in the 
no-aCT group; the OS curves differed significantly with a P-value 
< 0.001 (Fig. 1B).
Univariate analysis of the prognostic factors for DFS revealed 
that low rectal cancer, abdominoperineal resection (APR), open 
surgery, a tumor size > 2 cm at final pathology, retrieval of <12 
lymph nodes, CRM positivity (≤1 mm), R1 resection and aCT in-
completion were associated with poor DFS. Multivariate analysis 
indicated that open surgery (hazard ratio [HR], 2.243; 95% confi-
dence interval [CI], 1.099–4.578); P = 0.026), a tumor size >2 cm 
(HR, 4.168; 95% CI, 1.661–10.461; P = 0.002), retrieval of <12 
lymph nodes (HR, 2.438; 95% CI, 1.215–4.890; P = 0.012), CRM 
positivity (HR, 3.673; 95% CI, 1.579–8.542; P = 0.003) and aCT 
incompletion compared to aCT completion (HR, 7.052; 95% CI, 
2.323–21.410; P = 0.001) were independent prognostic factors for 
poor DFS (Table 2).
Univariate analysis of the prognostic factors for OS revealed that 
old age (≥60 years), low rectal cancer, a clinical stage of T3/4, APR, 
open surgery, a long hospital stay (>10 days), a pathologic stage of 
ypT4, retrieval of <12 lymph nodes, CRM positivity, R1 resection, 
no-aCT initiation compared to aCT initiation, and aCT incomple-
tion or no-aCT initiation compared to aCT completion were as-
sociated with a poor prognosis. In multivariate analysis, old age 
(≥60 years) (HR, 3.840; 95% CI, 1.204–12.251; P = 0.025), open 
Table 1. Patient demographics
Characteristic Completion Incompletion No-aCT P-value
Age ≥60 yr 63 (47.7) 3 (42.9) 10 (76.9) 0.123
Male sex 94 (71.2) 6 (85.7) 6 (46.2) 0.120
Body mass index  
(≥25 kg/m2)
26 (19.7) 1 (14.3) 3 (23.1) 0.896
ASA PS classification ≥ III 4 (3.0) 0 (0) 1 (7.7) 0.511
Preoperative CEA >5 μg/L 
(NA in 1)
50 (38.2) 3 (42.9) 2 (15.4) 0.251
Low rectal cancer  
(<AV 6 cm)
55 (41.7) 4 (57.1) 6 (46.2) 0.713
≥cT3 127 (96.2) 7 (100) 12 (92.3) 0.578
cN+ 96 (72.7) 5 (71.4) 9 (69.2) 0.920
nCRT regimen 0.116
   5-FU-based 99 (75.0) 4 (57.1) 13 (100)
   TS-1 & irinotecan 31 (23.5) 3 (42.9) 0 (0)
   Unknown 2 (1.5) 0 (0) 0 (0)
Operation 0.758
   Sphincter-saving 112 (84.8) 7 (100) 11 (84.6)
   APR 20 (15.2) 0 (0) 2 (15.4)
Minimally invasive surgery 83 (62.9) 2 (28.6) 9 (69.2) 0.167
Anastomotic leak 11 (8.3) 1 (14.3) 1 (7.7) 0.646
Hospital stay (>POD#10) 61 (46.2) 5 (71.4) 7 (53.8) 0.411
Histology (NA in 1) 0.051
   WD 17 (13.0) 2 (28.6) 0 (0)
   MD 108 (82.4) 5 (71.4) 10 (76.9)
   PD or mucinous 6 (4.6) 0 (0) 3 (23.1)
TRG (NA in 2) MG ≥3 93 (71.5) 6 (85.7) 12 (92.3) 0.257
ypT4 6 (4.5) 1 (14.3) 2 (15.4) 0.124
Tumor size >2 cm 78 (59.1) 5 (71.4) 9 (69.2) 0.697
Retrieved nodes <12 40 (30.3) 4 (57.1) 5 (38.5) 0.274
CRM ≤1 mm (NA in 16) 14 (11.9) 1 (20.0) 4 (30.8) 0.108
LVI (+) 10 (7.6) 0 (0) 1 (7.7) >0.999
R1 resection 4 (3.0) 0 (0) 2 (15.4) 0.108
aCT regimen 0.381
   5-FU-based 124 (93.9) 6 (85.7) NA
   FOLFOX 7 (5.3) 1 (14.3) NA
   Unknown 1 (0.8) 0 (0) NA
Values are presented as number (%).
ASA PS, American Society of Anesthesiologists physical status; CEA, carcinoem-
bryonic antigen; AV, anal verge; nCRT, neoadjuvant chemoradiotherapy; 5-FU, 
5-fluorouracil; APR, abdominoperineal resection; POD, postoperative day; NA, 
nonapplicable; WD, well-differentiated; MD, moderately differentiated; PD, poorly 
differentiated; TRG, tumor regression grade; CRM, circumferential resection mar-
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surgery (HR, 20.889; 95% CI, 3.684–118.455; P = 0.001), CRM 
positivity (HR, 3.965; 95% CI, 1.313-11.976; P = 0.015), aCT in-
completion compared to aCT completion (HR, 16.879; 95% CI, 
4.372–65.158; P < 0.001) and no-aCT initiation compared to aCT 
completion (HR, 26.371; 95% CI, 3.703–187.828; P = 0.001) were 
independent prognostic factors for poor OS (Table 3).
DISCUSSION
This study demonstrated that, compared with aCT completion, 
aCT incompletion after nCRT and TME was associated with poor 
DFS and OS, and lack of aCT initiation was also associated with 
poor OS in ypstage 2 rectal cancer patients. To the best of our 
knowledge, this is the first study to investigate the association be-
tween completion of planned aCT and survival outcomes in rectal 
cancer patients treated with nCRT and radical surgery.
For locally advanced rectal cancer, nCRT is a standard treat-
ment. Chemotherapeutic agents are used as radiosensitizers dur-
ing nCRT, and the doses are not sufficient for systemic control. 
Moreover, the time interval between diagnosis and aCT initiation 
Table 2. Prognostic factors of disease-free survival
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Low rectal cancer (<AV 6 cm) 2.052 (1.057–3.983) 0.034
Operation
   Sphincter-saving 1
   APR 2.259 (1.014–5.029) 0.032
Open surgery 2.834 (1.447–5.552) 0.002 2.243 (1.099–4.578) 0.026
Tumor size >2 cm 2.944 (1.289–6.724) 0.010 4.168 (1.661–10.461) 0.002
Retrieved nodes <12 2.714 (1.410–5.225) 0.003 2.438 (1.215–4.890) 0.012
CRM ≤1 mm 2.950 (1.325–6.565) 0.008 3.673 (1.579–8.542) 0.003
R1 resection   3.418 (1.043–11.196) 0.042
aCT
   Completion 1 1
   Incompletion   3.605 (1.263–10.293) 0.017 7.052 (2.323–21.410) 0.001
   No 1.759 (0.532–5.808) 0.345 1.730 (0.496–6.033) 0.390
HR, hazard ratio; CI, confidence interval; AV, anal verge; APR, abdominoperineal resection; CRM, circumferential resection margin; aCT, adjuvant chemotherapy.
Fig. 1. (A) Survival curves of disease-free survival. (B) Survival curves of overall survival. aCT, adjuvant chemotherapy.
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is approximately 4–5 months when long-course RT is applied. 
Therefore, a prolonged time interval between nCRT and surgery 
may result in failure to eradicate micrometastases by allowing 
subclinical tumor deposits to grow during the time required to 
achieve local control [8]. Many guidelines recommend periopera-
tive treatment for 6 months in rectal cancer, so aCT is conven-
tionally used for 4 months after nCRT and TME in pretreated 
rectal cancer patients. Given that the duration of planned aCT is 
shorter in rectal cancer than in colon cancer and that aCT initia-
tion is delayed in pretreated rectal cancer patients, it is logical to 
question the oncologic impact of aCT incompletion, along with 
that of aCT initiation.
The use of aCT and failure to complete aCT have been associ-
ated with poor survival in stage 3 and high-risk stage 2 colon can-
cer patients in previous studies [18-20]. In contrast, the benefit 
and proper duration of aCT have not been determined in pre-
treated rectal cancer patients. Previous RCTs on aCT after neoad-
juvant treatment in rectal cancer patients have reported no sur-
vival benefits [14-16]. The European Organization for Research 
and Treatment of Cancer 222921 trial initially indicated that aCT 
only benefited good responders exhibiting complete pathological 
remission or ypstage 1 cancer among pretreated rectal cancer pa-
tients; however, the 10-year follow-up results revealed no long-
term survival benefits for these patients [2, 14]. The long-term re-
sults from an Italian randomized trial (I-CNR-RT) and the Dutch 
Colorectal Cancer Group (randomized phase III trial (PROC-
TOR-SCRIPT trial) also demonstrated no benefit of aCT in pa-
tients who had undergone nCRT [15, 16]. However, these studies 
included good responders with ypN0 cancer, poor responders 
with ypN+ cancer and patients who did not complete their 
planned aCT schedules, exhibiting low compliance rates. Thus, 
the efficacy of aCT (42.9%–73.6%) might have been underesti-
mated [14-16].
Recent retrospective studies have attempted to identify specific 
subgroups who might benefit from aCT among rectal cancer pa-
tients who had undergone nCRT; however, these studies have had 
conflicting results [10-13, 17]. The subjects were mostly good re-
sponders with ypN0 cancer [10-13]. However, the completion 
status of planned aCT was not clarified in most of these studies 
[10-12].
Few studies have focused on ypstage 2 patients. In such patients, 
the omission of aCT might raise concerns about a poor prognosis, 
because these patients initially had locally advanced disease, and 
still exhibited an advanced ypT stage at final pathology, despite 
displaying node negativity. In one retrospective study that at-
tempted to identify subgroups that would benefit from aCT, no 
difference in DFS was found among ypstage 2 patients, despite 
benefits from aCT in the whole population (ypTanyNanyM0) 
[17].
When the no-aCT group was used as a reference, the aCT-in-
Table 3. Prognostic factors of overall survival
Variable
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Age ≥ 60 yr 3.047 (1.116–7.964) 0.023 3.840 (1.204–12.251) 0.023
Low rectal cancer (<AV 6 cm) 2.619 (1.003–6.841) 0.049
≥cT3 0.237 (0.069–0.820) 0.023
Operation
   Sphincter-saving 1
   APR 4.159 (1.671–10.349) 0.002
Open surgery 10.015 (2.275–44.093) 0.002 20.889 (3.684–118.455) 0.001
Hospital stay (>POD#10) 6.464 (1.476–28.313) 0.013
ypT4 3.720 (1.058–13.078) 0.041
Retrieved nodes < 12 3.299 (1.318–7.911) 0.010
CRM ≤ 1 mm 4.587 (1.698–12.390) 0.003 3.965 (1.313–11.976) 0.015
R1 resection 7.856 (2.219–27.810) 0.001
No-aCT vs. initiation of aCT 0.233 (0.066–0.821) 0.023
aCT
   Completion 1
   Incompletion 6.669 (2.122–20.957) 0.001 16.879 (4.372–65.158) <0.001
   No 5.575 (1.522–20.419) 0.009 26.371 (3.703–187.828) 0.001
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completion group did not exhibit any difference in OS (HR, 0.640; 
95% CI, 0.086–4.760; P = 0.663); however, the aCT-completion 
group exhibited better OS (HR, 0.038; 95% CI, 0.005–0.270; P = 
0.001). In addition, when compared to the aCT-completion 
group, the aCT-incompletion group displayed worse DFS and OS, 
and the no-aCT group exhibited worse OS. Therefore, based on 
these findings, it is essential to increase compliance with aCT ini-
tiation and ensure the completion of all planned cycles by encour-
aging patients and properly managing aCT-induced toxicity.
This study had some limitations due to its retrospective nature, 
such as possible selection bias and type 2 error. The sample size 
included in the analyses was small, with relatively large data cen-
sorship. If more cases of aCT-incompletion and no-aCT had been 
included, the statistical significance of the demographics of the 3 
groups may have been different, leading to a different interpreta-
tion of the results. Furthermore, the patients were heterogeneous 
with respect to their nCRT and aCT regimens; thus, our results 
cannot be completely applied in clinical practice. Therefore, it is 
imperative to conduct RCTs to collect firm evidence on the 
proper aCT duration that will improve the oncologic outcomes of 
pretreated rectal cancer patients.
In conclusion, this study demonstrated that only the aCT-com-
pletion group benefited from aCT after nCRT and TME; the no-
aCT and aCT-incompletion groups had poor prognoses.
In patients with ypstage 2 rectal cancer, aCT after nCRT and 
TME affected both DFS and OS; however, aCT incompletion did 
not have any survival benefit, implying that the initiation of aCT 
alone does not improve oncologic outcomes. Only aCT comple-
tion appears to have survival benefits in pretreated rectal cancer 
patients. Therefore, it is desirable to improve patient compliance 
with the completion of aCT, in light of its survival benefits in pa-
tients with ypstage 2 rectal cancer.
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